Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma

BACKGROUND. Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population. METHODS. Using the Nat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Margalit, Ofer, Mamtani, Ronac, Kopetz, Scott, Yang, Yu‐Xiao, Lawrence, Yaacov R., Abu‐Gazala, Samir, Reiss, Kim A., Golan, Talia, Halpern, Naama, Aderka, Dan, Giantonio, Bruce, Shacham‐Shmueli, Einat, Boursi, Ben
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693732/
https://ncbi.nlm.nih.gov/pubmed/30696723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0333
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares